Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

call at www.lexpharma.com. An archived version of the webcast will be available on the website through March 21, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements", including statements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon To Present At The BIO CEO & Investor Conference
2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Lexicon to Provide Third Quarter 2012 Financial Results
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
9. Lexicon to Provide Second Quarter 2012 Financial Results
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... , Aug. 31, 2015  Ascendant Solutions, Inc. ... today announced that its Healthcare subsidiary, Dougherty,s Holdings, has ... on the downtown square of Springtown, Texas ... than 35 years, this community-based pharmacy has provided retail ... of Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
... grounds, direct programming is superior,to cloning as a ... Nov. 20 Two major scientific,papers published this ... way to,generate patient-matched human pluripotent stem cells without ... or human or animal eggs.,Research groups in Wisconsin ...
... 20 The following statement,was released today by ... the Elizabeth Glaser Pediatric AIDS Foundation:, "Four ... Relief,(PEPFAR) began funding treatment and prevention, today,s report ... remains a devastating worldwide,pandemic, we are beginning to ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need 2
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... and stickers to keep little ones' safety top of mind at all times. , ... particular focus. According to the JPMA's Baby Safety Zone website, this year's theme is ...
(Date:8/31/2015)... ... ... The PT Outcomes Registry is an organized system for collecting data to evaluate ... being developed by the American Physical Therapy Association (APTA). , Al Amato, PT, MBA, ... FOTO Outcomes measures as one of the primary global outcomes measures to be used ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... a wealth of information for specific translation services within the medical and pharmaceutical ... incredible track record of successful work. , ITC Global Translations specializes in professional ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... insurance, announced today their new “ InstantQuote ” tool, which summarizes all available ... easy-to-understand format. The technology tool is designed to help India Network members make ...
(Date:8/31/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... August 31, ... ... has launched pre and postnatal fitness classes. , Starting September 1st ... classes are called "The Mom Bod" and "Healthy Body, Healthy Baby." , More ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... early-stage breast cancer that had spread to a nearby lymph ... therapy, women who just had the sentinel lymph node removed ... spread from the primary tumor) did not have worse survival ... (surgery to remove lymph nodes found in the armpit), according ...
... -- Researchers at the University at Buffalo have devised ... these medically important molecules from losing their shape and ... help speed the development of peptide-based drugs against diseases ... are simpler than existing techniques, one of which employs ...
... HealthDay Reporter , TUESDAY, Feb. 7 (HealthDay News) -- ... new "universal" influenza vaccine: one that might be effective against all ... as now happens. "Our hope is to develop a vaccine ... so we won,t need to keep making new flu vaccines each ...
... researchers from the University of California, San Diego School ... two distinct neuronal signaling pathways activated by a topical ... One pathway produces the therapeutic benefit; the other induces ... published in this week,s early online edition of the ...
... , TUESDAY, Feb. 8 (HealthDay News) -- In pregnant women, ... significantly higher blood pressure, new research suggests. The study ... had a lead level higher than about 1 microgram per ... lower than the safety thresholds set by the U.S Centers ...
... TUCSON, Ariz., Feb. 8, 2011 The Muscular Dystrophy ... support new research to advance understanding of disease processes ... ALS and other related neuromuscular diseases affecting more than ... made possible by generous public support of the MDA ...
Cached Medicine News:Health News:Limited lymph node removal for certain breast cancer does not appear to result in poorer survival 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:'Universal' Flu Vaccine Shows Promise in Early Trial 2Health News:'Universal' Flu Vaccine Shows Promise in Early Trial 3Health News:The hitch in the drug? The itch in the drug 2Health News:Lead Exposure May Raise Blood Pressure in Pregnancy 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Children's hospital hand drill, hexagonal handle, twist drill diameter 4.2 mm....
Hudson Drill hand drill....
Hudson Downs hand drill....
Medicine Products: